Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, focusing on specific companies and their recent performance, driven by various strategic announcements and market conditions. Hong Kong Stock Market Summary - China General Nuclear Power Corporation (01164) rose over 6% following US Energy Secretary Chris Wright's suggestion to consider expanding strategic uranium reserves, indicating potential upward price adjustments for uranium [1] - Yunfeng Financial (00376) fell over 18% after announcing a rights issue at a discount of approximately 16.8%, aiming to raise about HKD 1.15 billion [1] - GCL-Poly Energy Holdings (03800) increased over 2% as it plans a rights issue at a discount of about 8.73%, targeting net proceeds of HKD 5.392 billion for structural adjustments in polysilicon production [1] - Lion Group Holding (02562) surged over 6% after signing a letter of intent to acquire a leading AI and blockchain company, expanding its digital finance footprint [1] - Pharmaron Beijing Co., Ltd. (02617) skyrocketed over 53% after being included in the Hong Kong Stock Connect list, with a cumulative increase of nearly 10 times since its inclusion, and northbound investors adding over HKD 300 million in two days [1] - Anta Sports Products (02020) rose over 2% as retail sales of sports goods showed rapid growth in the first eight months, indicating marginal improvement in sales [1] - SF Technology (09699) increased over 5% after launching its "SoFast" brand in Macau, marking a significant step in its overseas business expansion [1] - Shanghai Fudan (01385) rose over 6% as Morgan Stanley reported the company is well-prepared for supply chain disruptions, with limited demand impact expected [2] - Tianyue Advanced (02631) increased over 1% after being included in the Hong Kong Stock Connect, with silicon carbide expected to see new market growth [2] - Valiant Co., Ltd. (09887) rose over 10% after announcing the completion of the first patient dosing in a trial for its core product LBL-024 for melanoma [2] US Stock Market Summary - Tesla (TSLA.US) rose 3.56% as the head of its German factory announced an increase in production plans for Q3 and Q4 due to strong sales data [3] - NVIDIA (NVDA.US) fell 0.04% as it faces further investigation for violating antitrust laws [3] - Hesai Technology (HSAI.US) increased 4.31% after announcing a partnership with a leading US Robotaxi company, securing over USD 40 million in lidar orders [3] - XPeng Motors (XPEV.US) rose 2.20% after formalizing a deep cooperation with Magna Steyr in Austria, marking the start of local production in Europe [3] - NIO (NIO.US) increased 4.34% as it announced the NIO Day 2025 event, scheduled for September 20, where the new ES8 will be launched [3] - Apple (AAPL.US) rose 1.12% as Morgan Stanley reported that demand for the iPhone 17 series exceeded that of the previous year's iPhone 16 series during its first week of launch [4] - Fangdd Network Group (DUO.US) fell 9.17% following the National Bureau of Statistics' report indicating a decline in residential property prices in August [3] - Alibaba (BABA.US) rose 1.92% ahead of the 2025 Cloud Summit scheduled for September 24-26 in Hangzhou [4] - ASML Holding (ASML.US) increased 6.56% after announcing a EUR 1.3 billion investment in French AI startup Mistral AI, becoming its largest shareholder [4] - Bilibili (BILI.US) rose 6.40% as it announced the upcoming public test of its new strategy card game, "Three Kingdoms: Hundred Generals Card" [4] - Oracle (ORCL.US) increased 3.41% as management disclosed that its cloud infrastructure revenue is set to experience steep growth [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 藥捷安康（南京）科技股份有限公司 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 自願性公告 股價及成交量的異常變動 本公告由藥捷安康（南京）科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發。 本公司董事會（「董事會」）注意到，本公司股份（「股份」）之交易價格及成交量近 期出現異常變動。經就本公司作出在有關情況下屬合理的一切查詢後，董事會確 認，概不知悉(i)導致股份出現該等股價及成交量異常變動之任何原因；或(ii)任何 須予公佈以避免股份出現虛假市場之資料；或(iii)根據上市規則第13.09(2)條及證 券及期貨條例（香港法例第571章）第XIVA部須予披露之任何內幕消息。 董事會亦確認 ...

Core Viewpoint - The stock price of药捷安康 (02617.HK) has experienced a significant surge, with a notable increase of over 50% during intraday trading on September 16, reaching 608.5 HKD per share, resulting in a total market capitalization of 240.1 billion HKD [1] Group 1 - The stock price of药捷安康 has shown a continuous upward trend, with a cumulative increase of 566.11% over the four trading days from September 11 to September 16 [1]

每经AI快讯，港股药捷安康-B(02617.HK)早盘再涨超60%，高见679.5港元。截至发稿，涨50.6%，报 625.5港元，成交额11.77亿港元，总市值一度突破2500亿港元。 ...

Market Overview - The Hong Kong stock market opened slightly higher on September 16, with the Hang Seng Index at 26,536 points, up 0.34%, and the Hang Seng Tech Index at 6,070 points, up 0.45% [1] Focus Companies - **Yaojie Ankang-B (02617.HK)**: The stock saw a maximum increase of over 60% in early trading, reaching a new high of 679.5 HKD. There was a net inflow of 143 million HKD from southbound funds yesterday. However, some analysts suggest that the stock may be overvalued and highly concentrated, advising ordinary investors to refrain from participation [3] - **Longpan Technology (02465.HK)**: Announced a procurement cooperation agreement with CATL for the sale of 157,500 tons of lithium iron phosphate cathode materials from Q2 2026 to 2031, with a total sales value exceeding 6 billion HKD. The stock opened over 14% higher [5] - **Ningde Times (03750.HK)**: Opened 2.8% higher at 478 HKD, reaching a new high since its listing [5] - **Yunfeng Financial (00376.HK)**: Announced a placement of 19.1 million new shares at 6.1 HKD per share, raising approximately 1.17 billion HKD. The stock fell over 10% in early trading [7] - **Hesai (02525.HK)**: Listed on the Hong Kong Stock Exchange today, opening with a rise of over 7% and later increasing to a 10% gain [9] Sector Performance - The technology sector showed mixed results, with Bilibili-W (09626.HK) up over 2% and JD Group-SW (09618.HK) down over 0.5%. Gold stocks generally rose, with Shandong Gold (01787.HK) increasing over 3%. The automotive sector was active, with Li Auto-W (02015.HK) up over 3%, and lithium battery stocks continued their upward trend, with Ningde Times rising over 2% [8] Market Outlook - According to China Merchants Securities, the Hong Kong market is primarily driven by liquidity, with expectations for a new round of increases due to improved liquidity conditions. Factors such as the Federal Reserve's interest rate cuts, easing of tight liquidity in the Hong Kong market, continuous inflow of southbound funds, and resolution of mid-term profit concerns are contributing to this outlook [8]

消息面上，消息面上，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生 效。数据显示，入通后北水资金连续加仓药捷安康，9月12日、9月15日，北水资金分别加仓药捷安康 1.8亿、1.42亿港元。 公开资料显示，药捷安康专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。截至2025年6 月30日，该公司主要管线包括六款临床阶段候选产品及多款临床前阶段候选产品。值得注意的是，药捷 安康此前发布中期业绩，上半年集团未取得主营业务收入，其他收入及收益由2024年上半年的1040万元 下降至360万元，降幅达65.1%。此外，公司核心产品替恩戈替尼(TT-00420)近期迎来多重利好。 药捷安康-B(02617)早盘再涨超60%，高见679.5港元，入通以来累计涨幅已接近10倍。截至发稿，涨 50.6%，报625.5港元，成交额11.77亿港元，总市值一度突破2500亿港元。 ...

Core Viewpoint - The stock of药捷安康-B (02617) has surged over 60% in early trading, reaching a high of 679.5 HKD, with a cumulative increase of nearly 10 times since its entry into the market [1] Group 1: Stock Performance - As of the latest update, the stock is up 50.6%, trading at 625.5 HKD, with a transaction volume of 1.177 billion HKD and a market capitalization that briefly surpassed 250 billion HKD [1] - Following its inclusion in the Hong Kong Stock Connect program effective September 8, there has been a continuous increase in investment from northbound funds, with purchases of 180 million HKD and 142 million HKD on September 12 and September 15, respectively [1] Group 2: Company Overview -药捷安康 focuses on the discovery and development of small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidate products and multiple preclinical-stage candidates in its pipeline [1] Group 3: Financial Performance - The company reported no revenue from its main business in the first half of the year, with other income declining from 10.4 million HKD in the first half of 2024 to 3.6 million HKD, a decrease of 65.1% [1] - The core product,替恩戈替尼 (TT-00420), has recently received multiple favorable developments [1]

每经AI快讯，9月16日，药捷安康-B涨超50%，股价最高触及679.5港元。 ...

上市才两个多月，药捷安康市值已经翻了近20倍。6月23日，药捷安康登陆港股，上市当日股价即 大涨79%，但市值仅为93亿港元。 据招股书，药捷安康总股本约3.97亿股，IPO仅发售约1528 万股，除去基石投资者认购的约979万股，实际流通股只有 549万股。 作者：张铃 封图：图虫创意 9月15日，药捷安康（02617.HK）暴涨115.7%，报415港元/股，市值达到1648亿港元，成为港股 18A 市 值 排 名 第 二 的 创 新 药 企 ， 仅 次 于 " 创 新 药 一 哥 " 百 济 神 州 （ONC.NASDAQ/06160.HK/688235.SH）。 另外，9月10日，药捷安康公告，其核心产品替恩戈替尼联合氟维司群治疗经治失败的激素受体阳 性（HR+）且人表皮生长因子受体2阴性或低表达（HER2-）的复发或转移性乳腺癌II期临床试 验，已于9月10日获得国家药监局临床默示许可。 药捷安康是处于临床阶段的创新药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新 疗法，尚无商业化产品。截至2025年6月30日，其有六款临床阶段候选产品及多款临床前阶段候选 产品，最核心的产品即为替恩戈替尼 ...